Friday’s Pre-Market Insights: Heron Therapeutics Inc (HRTX), Prima Biomed Ltd. (PBMD), Transgenomic Inc (TBIO)

Heron Therapeutics Inc (NASDAQ:HRTX) shares soared over 38% to $17.10 in pre-market trading after the company announced positive, top-line results from its recently completed Phase 3 MAGIC study. MAGIC evaluated the efficacy and safety of the Company’s 5-HT3 receptor antagonist product candidate SUSTOL for the prevention of delayed-onset chemotherapy-induced nausea and vomiting (CINV) following administration of highly emetogenic chemotherapy (HEC) agents.

On the ratings front, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on HRTX, with a price target of $40, in a report issued on May 15. The current price target represents a potential upside of 224% from where the stock is currently trading. According to, Aschoff has a total average return of 7.6%, a 55.1% success rate, and is ranked #426 out of 3610 analysts.

Prima Biomed Ltd. (NASDAQ:PBMD) shares increased 17% to $2.89 in Friday’s pre-market trading following news that the company has made substantial progress with its lead product, IMP321. As such, the company reported that it has filed a provisional patent application over the use of IMP321 in combination with immune checkpoint inhibitors.

Transgenomic Inc (NASDAQ:TBIO) shares increased nearly 22% to $2.31 after the company announced the launch of its new Multiplexed ICE COLD-PCR™ (MX-ICP) CLIA service for mutation detection in cancer patients to enable more informed diagnoses, better treatment decisions and ongoing patient monitoring.


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts